☆ 4.8 Meeting Abstract

PD-1/PD-L1 blockade enhances MDM2 inhibitor activity in p53 wild-type cancers

CANCER RESEARCH (2018)

期刊

CANCER RESEARCH

卷 78, 期 13, 页码 -

出版社

AMER ASSOC CANCER RESEARCH

DOI: 10.1158/1538-7445.AM2018-5560

关键词

-

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Oncology

First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

Seyed Pairawan, Ming Zhao, Erkan Yuca, Allen Annis, Kurt Evans, David Sutton, Luis Carvajal, Jian-Guo Ren, Solimar Santiago, Vincent Guerlavais, Argun Akcakanat, Coya Tapia, Fei Yang, Priya Subash Chandra Bose, Xiaofeng Zheng, Ecaterina Ileana Dumbrava, Manuel Aivado, Funda Meric-Bernstam

Summary: MDM2/MDMX proteins are often elevated in ER+ breast cancer. ALRN-6924 showed significant activity in WT-TP53 cancer cell lines, particularly in combination with chemotherapeutic agents such as paclitaxel. The combination of ALRN-6924 with chemotherapy demonstrated enhanced antitumor efficacy and increased p21 expression in ER+ breast cancer models.

BREAST CANCER RESEARCH (2021)

添加到收藏夹

Review Immunology

The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives

Jamal Majidpoor, Keywan Mortezaee

Summary: The interaction between PD-L1 and PD-1 is crucial for immune evasion in cancers, with PD-L1 positivity generally associated with higher responses to immune checkpoint inhibition (ICI) but also poor prognosis. Triple negative breast cancer (TNBC) is aggressive, but shows meaningful responses to ICI. Combining anti-PD-1/PD-L1 with immune modulatory drugs has shown significant clinical benefits.

CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia

Eytan M. Stein, Daniel J. DeAngelo, Joerg Chromik, Manik Chatterjee, Sebastian Bauer, Chia-Chi Lin, Cristina Suarez, Filip de Vos, Neeltje Steeghs, Philippe A. Cassier, David Tai, Jean-Jacques Kiladjian, Noboru Yamamoto, Rogier Mous, Jordi Esteve, Hironobu Minami, Stephane Ferretti, Nelson Guerreiro, Christophe Meille, Rajkumar Radhakrishnan, Bernard Pereira, Luisa Mariconti, Ensar Halilovic, Claire Fabre, Cecilia Carpio

Summary: This phase I study investigated the recommended dose for expansion of siremadlin, a p53-MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. The study found recommended doses/regimens for future combination studies. Patients with solid tumors and hematologic malignancies differed in terms of treatment-related adverse events.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells

Jingyao Tu, Haoran Xu, Li Ma, Chunya Li, Wan Qin, Xinyi Chen, Ming Yi, Li Sun, Bo Liu, Xianglin Yuan

Summary: This study investigated the therapeutic potential of nintedanib and alpha PD-L1 combination therapy in tumor treatment. The results showed significant improvements in the antitumor effects and positive impact on lung complications with this combination therapy.

THERANOSTICS (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer

Yaohui Gao, Dexi Bi, Ruting Xie, Man Li, Jing Guo, Hu Liu, Xianling Guo, Juemin Fang, Tingting Ding, Huiyuan Zhu, Yuan Cao, Meichun Xing, Jiayi Zheng, Qing Xu, Qian Xu, Qing Wei, Huanlong Qin

Summary: The research found that high levels of F. nucleatum are associated with improved therapeutic responses to PD-1 blockade in patients with CRC, and F. nucleatum also enhances the antitumor effects of PD-L1 blockade on CRC. Furthermore, F. nucleatum induces PD-L1 expression and increases the accumulation of interferon-gamma (IFN-gamma)(+) CD8(+) tumor-infiltrating lymphocytes.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Review Immunology

Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy

Ali Razaghi, Mickael Durand-Dubief, Nele Brusselaers, Mikael Bjornstedt

Summary: PD-1 and PD-L1 play crucial roles in immune regulation and can be targeted for cancer treatment. Blocking PD-1/PD-L1 can enhance tumor recognition by activated T cells and combining it with type I interferon (IFN) can further improve therapeutic efficacy.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Ming Yi, Xiaoli Zheng, Mengke Niu, Shuangli Zhu, Hong Ge, Kongming Wu

Summary: Antibodies targeting PD-1/PD-L1 revive immune response against cancer cells, but the low response rate calls for combination therapies. Combining with chemotherapy, radiotherapy, and other treatments can achieve better outcomes, and individualized combination selection is needed to overcome treatment resistance.

MOLECULAR CANCER (2022)

添加到收藏夹

Article Immunology

Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes

Tania Afroj, Atsushi Mitsuhashi, Hirokazu Ogino, Atsuro Saijo, Kenji Otsuka, Hiroto Yoneda, Makoto Tobiume, Na Thi Nguyen, Hisatsugu Goto, Kazuya Koyama, Masamichi Sugimoto, Osamu Kondoh, Hiroshi Nokihara, Yasuhiko Nishioka

Summary: Fibrocytes, a type of collagen-producing, monocyte-derived cells, have been found to play a role in the tumor microenvironment, particularly under antiangiogenic therapy. These cells express costimulatory molecules, such as CD80 and CD86, and coinhibitory molecule PD-L1, which can influence the proliferation of CD8(+) T cells. The findings suggest that fibrocytes infiltrating tumor sites may enhance anti-tumor immunity when combined with PD-L1/PD-1 blockade.

JOURNAL OF IMMUNOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations

Seyed Pairawan, Argun Akcakanat, Scott Kopetz, Coya Tapia, Xiaofeng Zheng, Huiqin Chen, Min Jin Ha, Yasmeen Rizvi, Vijaykumar Holla, Jing Wang, Kurt W. Evans, Ming Zhao, Naifa Busaidy, Bingliang Fang, Jack A. Roth, Ecaterina Ileana Dumbrava, Funda Meric-Bernstam

Summary: Combination therapy with MEK inhibitor selumetinib and MDM2 inhibitor KRT-232 was evaluated in colon and thyroid cancer models. The study showed that the combination therapy had better antitumor efficacy than single drug therapy in both in vitro and in vivo settings.

SCIENTIFIC REPORTS (2022)

添加到收藏夹

Review Immunology

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

Qing Tang, Yun Chen, Xiaojuan Li, Shunqin Long, Yao Shi, Yaya Yu, Wanyin Wu, Ling Han, Sumei Wang

Summary: PD-1 and PD-L1 play important roles in the progression of human cancers and are promising biomarkers for cancer therapy. The interaction between PD-1 and PD-L1 is a crucial mechanism by which human tumors evade the immune system. PD-1/PD-L1 immune-checkpoint inhibitors have shown promising therapeutic effects in human cancers, with combination therapy and predictive models as potential future directions.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin

Shaomeng Chen, Xiuman Zhou, Xin Yang, Wanqiong Li, Shuzhen Li, Zheng Hu, Chen Ling, Ranran Shi, Juan Liu, Guanyu Chen, Nazi Song, Xianxing Jiang, Xinghua Sui, Yanfeng Gao

Summary: This study demonstrates the synergistic effects of lactate/GPR81 blockade and metformin in inhibiting cancer cell growth, as well as enhancing immune cell functions and impacting PD-1 expression. The dual blockade strategy significantly enhances the anti-tumor effects of metformin, potentially leading to tumor regression.

BIOMOLECULES (2021)

添加到收藏夹

Article Immunology

A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

Ander Puyalto, Maria Rodriguez-Remirez, Ines Lopez, Fabiola Iribarren, Jon Ander Simon, Marga Ecay, Maria Collantes, Anna Vilalta-Lacarra, Alejandro Francisco-Cruz, Jose Luis Solorzano, Sergio Sandiego, Ivan Penuelas, Alfonso Calvo, Daniel Ajona, Ignacio Gil-Bazo

Summary: This study demonstrates the use of [Zr-89]-anti-PD-1 immuno-PET as a safe and feasible imaging modality to accurately assess the response to PD-1/PD-L1 blockade in NSCLC.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Antitumor Effect of Korean Red Ginseng through Blockade of PD-1/PD-L1 Interaction in a Humanized PD-L1 Knock-In MC38 Cancer Mouse Model

Eun-Ji Lee, Ju-Hye Yang, Hye Jin Yang, Chong-Kwan Cho, Jang-Gi Choi, Hwan-Suck Chung

Summary: Korean Red Ginseng extract (RGE) blocks the interaction between PD-1 and PD-L1, inhibits tumor growth, and enhances cytotoxic T cell activity, suggesting its potential as an immunotherapy for cancer treatment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Article Medicine, Research & Experimental

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC

Carminia Maria Della Corte, Vincenza Ciaramella, Kavya Ramkumar, Giovanni Vicidomini, Alfonso Fiorelli, Valerio Nardone, Salvatore Cappabianca, Immacolata Cozzolino, Federica Zito Marino, Gaetano Di Guida, Qi Wang, Robert Cardnell, Carl Michael Gay, Davide Ciardiello, Erika Martinelli, Teresa Troiani, Giulia Martini, Stefania Napolitano, Jing Wang, Lauren Averett Byers, Fortunato Ciardiello, Floriana Morgillo

Summary: The combined inhibition of MEK and PD-L1 shows significant synergistic effect in immune-dependent cancer cell death in non-small cell lung cancer (NSCLC), but may lead to the activation of the Ido-1 pathway as an escape mechanism.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Recent findings on the role of wild-type and mutant p53 in cancer development and therapy

Mehregan Babamohamadi, Esmaeil Babaei, Burhan Ahmed Salih, Mahshid Babamohammadi, Hewa Jalal Azeez, Goran Othman

Summary: The p53 protein is a tumor suppressor that regulates various cellular processes and is closely related to cancer development. It can be used as a biomarker for tumor progression and a target for cancer treatment. This review discusses the contribution of wild-type p53 loss of function, its role in ferroptosis and targeted therapy, and challenges and solutions in p53-related drug delivery systems.

FRONTIERS IN MOLECULAR BIOSCIENCES (2022)

添加到收藏夹

Article Oncology

Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy

Leslie K. Ballas, Chunqiao Luo, Eugene Chung, Amar U. Kishan, Igor Shuryak, David I. Quinn, Tanya Dorff, Shamim Jhimlee, Raymond Chiu, Andre Abreu, Richard Jennelle, Monish Aron, Susan Groshen

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)

添加到收藏夹

Editorial Material Urology & Nephrology

Racial Discrepancies in Overall Survival among Men Treated with 223Radium

Anishka A. D'Souza, David I. Quinn

JOURNAL OF UROLOGY (2020)

添加到收藏夹

Article Oncology

Cancer transcriptomic profiling from rapidly enriched circulating tumor cells

Gareth J. Morrison, Alexander T. Cunha, Nita Jojo, Yucheng Xu, Yili Xu, Eric Kwok, Peggy Robinson, Tanya Dorff, David Quinn, John Carpten, Zarko Manojlovic, Amir Goldkorn

INTERNATIONAL JOURNAL OF CANCER (2020)

添加到收藏夹

Article Oncology

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry

Oliver Sartor, Andrew J. Armstrong, Chiledum Ahaghotu, David G. McLeod, Matthew R. Cooperberg, David F. Penson, Philip W. Kantoff, Nicholas J. Vogelzang, Arif Hussain, Christopher M. Pieczonka, Neal D. Shore, David I. Quinn, Eric J. Small, Elisabeth I. Heath, Ronald F. Tutrone, Paul F. Schellhammer, Matthew Harmon, Nancy N. Chang, Nadeem A. Sheikh, Bruce Brown, Stephen J. Freedland, Celestia S. Higano

PROSTATE CANCER AND PROSTATIC DISEASES (2020)

添加到收藏夹

Article Oncology

Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer

Risa L. Wong, Mai T. Duong, Catherine M. Tangen, Neeraj Agarwal, Heather H. Cheng, Nicholas J. Vogelzang, Maha Hussain, Ian M. Thompson, David I. Quinn, Evan Y. Yu

PROSTATE CANCER AND PROSTATIC DISEASES (2020)

添加到收藏夹

Article Oncology

Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer

Mitchell E. Gross, David B. Agus, Tanya B. Dorff, Jacek K. Pinski, David Quinn, Olga Castellanos, Patrick Gilmore, Jean C. Shih

Summary: Phenelzine showed efficacy in patients with biochemical recurrent castrate-sensitive prostate cancer, with mild treatment-related toxicities observed in most patients and rare significant and reversible cardiovascular toxicities. Treatment reduced anxiety symptoms significantly, but did not change depressive symptoms. Therapies targeting MAOA may provide a new avenue for treating recurrent prostate cancer patients.

PROSTATE CANCER AND PROSTATIC DISEASES (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Protocol for a multi-centre, definitive randomised controlled trial of the effectiveness of Individual Placement and Support for employment support among people with alcohol and drug dependence

John Marsden, Paul Anders, Helen Clark, Kyriacos Colocassis, Brian Eastwood, Jonathan Knight, Alexandra Melaugh, David Quinn, Virginia Wright, Jez Stannard

TRIALS (2020)

添加到收藏夹

Review Oncology

High-Dimensional Immune Monitoring for Chimeric Antigen Receptor T Cell Therapies

Sujata Sharma, David Quinn, J. Joseph Melenhorst, Iulian Pruteanu-Malinici

Summary: This review highlights the use of state-of-the-art R-based pipelines for differential analyses of cytometry data, focusing on CAR T cell therapies. These pipelines, based on publicly available R libraries, offer a systematic and functional approach to analyzing high-dimensional flow cytometry experiments.

CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2021)

添加到收藏夹

Article Oncology

Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment

Hui Qin Wang, Iain J. Mulford, Fiona Sharp, Jinsheng Liang, Sema Kurtulus, Gina Trabucco, David S. Quinn, Tyler A. Longmire, Nidhi Patel, Roshani Patil, Matthew D. Shirley, Yan Chen, Hao Wang, David A. Ruddy, Claire Fabre, Juliet A. Williams, Peter S. Hammerman, Jennifer Mataraza, Barbara Platzer, Ensar Halilovic

Summary: MDM2 inhibition triggers adaptive immunity and further enhances antitumor immune response by blocking the PD-1/PD-L1 pathway. In patients with wild-type p53 tumors, combining MDM2 inhibitors with checkpoint blocking antibodies may have potential therapeutic efficacy.

CANCER RESEARCH (2021)

添加到收藏夹

Meeting Abstract Hematology

Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-Charge TM Platform

Adam S. Sperling, Sarah Nikiforow, Omar Nadeem, Clifton C. Mo, Jacob P. Laubach, Kenneth C. Anderson, Alejandro Alonso, Shuntaro Ikegawa, Rao Prabhala, Diego Hernandez Rodriguez, Heather Daley, Kit L. Shaw, Yohei Arihara, Soudeh Ansari, David S. Quinn, David Pearson, Anniesha Hack, Louise M. Treanor, Dexiu Bu, Jennifer Mataraza, Lawrence Rispoli, Marc Credi, Jerome Ritz, Serena De Vita, Nikhil C. Munshi

BLOOD (2021)

添加到收藏夹

Article Oncology

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

Michael J. Dickinson, Pere Barba, Ulrich Jaeger, Nirav N. Shah, Didier Blaise, Javier Briones, Leyla Shune, Nicolas Boissel, Attilio Bondanza, Luisa Mariconti, Anne-Laure Marchal, David S. Quinn, Jennifer Yang, Andrew Price, Akash Sohoni, Louise M. Treanor, Elena J. Orlando, Jennifer Mataraza, Jaclyn Davis, Darlene Lu, Xu Zhu, Boris Engels, Laure Moutouh-de Parseval, Jennifer L. Brogdon, Michele Moschetta, Ian W. Flinn

Summary: CAR-T cell product quality and stemness are crucial for treatment efficacy. YTB323, a novel CAR-T cell therapy, showed enhanced in vivo expansion and antitumor activity at lower doses in preclinical and preliminary clinical trials. It also exhibited promising safety and clinical response rates, supporting its continued development for relapsed/refractory diffuse large B-cell lymphoma.

CANCER DISCOVERY (2023)

添加到收藏夹

Meeting Abstract Oncology

On-target peripheral and tumor immune microenvironment modulation in patients treated with lacnotuzumab (anti-CSF1, MCS110) + spartalizumab.

Jincheng Wu, Shuqi Chen, Guillaume Baneyx, Anne-Laure Marchal, David S. Quinn, Miguel Martin, Andres Cervantes, Janna Sand-Dejmek, Jennifer Marie Mataraza

CANCER RESEARCH (2021)

添加到收藏夹

Meeting Abstract Oncology

A MULTIPARAMETER FLOW CYTOMETRY ASSAY TO MONITOR NATURAL KILLER CELL PROLIFERATION AND ACTIVATION IN IMMUNO-ONCOLOGY CLINICAL TRIALS

Jennifer Tsau, Brittney Atzmiller, David Quinn, Tanya Mulvey, Sema Kurtulus, Jennifer Mataraza, Shabnam Tangri, Naveen Dakappagari, Ghanashyam Sarikonda

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria

Erik M. Velez, Bhushan Desai, Lingyun Ji, David Quinn, Patrick M. Colletti, Hossein Jadvar

THERANOSTICS (2020)

添加到收藏夹

Meeting Abstract Oncology

Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket; trial

J. Harding, J. Cleary, G. Shapiro, I. Brana, V. Moreno, D. Quinn, M. Borad, S. Loi, I. Spanggaard, S. Stemmer, M. Dujka, R. Cutler, F. Xu, L. Eli, S. Macia, A. Lalani, R. Bryce, F. Meric Bernstam, D. Solit, D. Hyman, S. Piha-Paul

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.